

etanercept 50mg subcutaneous injection (Enbrel^o) for rheumatoid arthritis No. (305/06)

Wyeth Pharmaceuticals

Product Update - New Formulation

4 August 2006

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

etanercept 50mg subcutaneous injection (Enbrel) is accepted for use within NHS Scotland for the treatment of patients with rheumatoid arthritis for whom treatment with etanercept is considered appropriate. Etanercept is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults, either alone or in combination with methotrexate when the response to disease modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate or for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

The 50mg formulation facilitates once weekly administration of etanercept at no additional cost over the existing 25mg formulation that is administered twice weekly.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 14 July 2006.

Chairman Scottish Medicines Consortium

> Secretariat -Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org

> > Chairman Professor David Webb